What are the recommended adult dosing guidelines for captopril for hypertension, heart failure, post‑myocardial infarction, and diabetic nephropathy, including dose adjustments for renal impairment and elderly patients?

Captopril Dosing Guidelines

Captopril dosing varies by indication: for hypertension, start at 25 mg twice or three times daily and titrate to 25–150 mg two or three times daily; for heart failure, initiate at 6.25–12.5 mg three times daily in volume-depleted patients or 25 mg three times daily otherwise, targeting 50–100 mg three times daily; for post-myocardial infarction, begin with 6.25 mg, then 12.5 mg three times daily, advancing to 50 mg three times daily; and for diabetic nephropathy, use 25 mg three times daily. 1

Hypertension Dosing

Initial Therapy

• Start captopril at 25 mg two or three times daily after a one-week trial with a diuretic (typically hydrochlorothiazide 25 mg twice daily). 1
• If blood pressure remains uncontrolled after one to two weeks, increase the dose of captopril while continuing the diuretic. 1
• Titrate to 50 mg two or three times daily, then if needed to 100 mg two or three times daily, and finally to 150 mg two or three times daily (maximum 450 mg/day). 1
• Allow at least two weeks between dose increases to assess response. 1

Severe or Accelerated Hypertension

• When prompt blood pressure reduction is required and discontinuation of current therapy is not feasible, initiate captopril at 25 mg two or three times daily under close medical supervision while continuing diuretics but stopping other antihypertensives. 1
• The daily dose may be increased every 24 hours or less under continuous supervision until satisfactory control is achieved or the maximum dose (450 mg/day) is reached. 1
• Addition of a loop diuretic (e.g., furosemide) may be indicated in this setting. 1

Evidence for Lower Doses

• Clinical trials demonstrate that captopril 37.5 mg/day (12.5 mg three times daily) is as effective as 150 mg/day for uncomplicated hypertension, with blood pressure reductions averaging 10–14/9–11 mm Hg. 2
• Both twice-daily and three-times-daily regimens at equivalent total daily doses produce similar antihypertensive effects. 3
• The KDOQI guidelines recommend a starting dose of 6.25–25 mg three times daily, with a goal dose of 25–150 mg two or three times daily for diabetic kidney disease with hypertension. 4

Heart Failure Dosing

Standard Initiation

• For most patients, begin with 25 mg three times daily. 1
• After reaching 50 mg three times daily, delay further dose increases for at least two weeks to assess response. 1
• Target maintenance dose is 50–100 mg three times daily (maximum 450 mg/day). 1
• Captopril should be used in conjunction with a diuretic and digitalis. 1

Volume-Depleted or Hypotensive Patients

• In patients vigorously treated with diuretics who may be hyponatremic or hypovolemic, start with 6.25 or 12.5 mg three times daily to minimize hypotensive effects. 1
• Titration to the usual daily dosage can then occur over the next several days. 1
• The European heart failure guidelines recommend a starting dose of 6.25 mg three times daily with a target of 50–100 mg three times daily. 5

Monitoring and Titration

• Double the dose at intervals of not less than two weeks. 5
• Aim for the target dose or, failing that, the highest tolerated dose—some ACE inhibitor is better than none. 5
• Monitor blood chemistry (urea, creatinine, potassium) and blood pressure with each dose adjustment. 5

Post-Myocardial Infarction Dosing

• The target maintenance dose is 50 mg three times daily. 1
• Therapy may be initiated as early as three days following myocardial infarction. 1
• Begin with a single test dose of 6.25 mg, then initiate therapy at 12.5 mg three times daily. 1
• Increase to 25 mg three times daily over the next several days, then advance to the target of 50 mg three times daily over the next several weeks as tolerated. 1
• Captopril may be used with other post-MI therapies including thrombolytics, aspirin, and beta-blockers. 1
• The 2015 AHA guidelines recommend oral ACE inhibitors within the first 24 hours in STEMI patients with pulmonary congestion or left ventricular ejection fraction <40%, absent hypotension (systolic BP <100 mm Hg). 6
• Long-term captopril after MI significantly reduces mortality (19% relative reduction in the SAVE trial) when titrated to 50 mg three times daily. 7

Diabetic Nephropathy Dosing

• The recommended dose is 25 mg three times daily for long-term treatment. 1
• Other antihypertensives (diuretics, beta-blockers, centrally acting agents, or vasodilators) may be added if additional blood pressure lowering is required. 1
• The KDOQI guidelines specify a starting dose of 6.25–25 mg three times daily with a goal of 25–150 mg two or three times daily for diabetic kidney disease. 4
• In hypertensive diabetic women with nephropathy, captopril 144 mg/day (approximately 50 mg three times daily) significantly reduced proteinuria by 48% while maintaining stable creatinine clearance. 8

Renal Impairment Adjustments

• Because captopril is primarily renally excreted, patients with impaired renal function require reduced initial doses and slower titration (one- to two-week intervals). 1
• These patients reach higher steady-state levels for a given dose and may respond to smaller or less frequent doses. 1
• After achieving the desired effect, slowly back-titrate to determine the minimal effective dose. 1
• When concomitant diuretic therapy is needed in severe renal impairment, use a loop diuretic (e.g., furosemide) rather than a thiazide. 1
• In chronic renal failure with hypertension, captopril 300 mg daily or less effectively controls blood pressure; side effects appear dose-dependent, and reduced dosages should be used. 9
• The 2009 geriatric consensus guidelines did not reach consensus on specific captopril dose adjustments for renal impairment in older adults. 10

Elderly Patient Considerations

• Moderate-dose ACE inhibitors (captopril 75 mg/day, enalapril 10 mg/day, or lisinopril 10 mg/day) are significantly associated with hyperkalemia in older adults. 11
• Older adults are more susceptible to ACE inhibitor-related reductions in renal function. 11
• Monitor renal function and serum potassium within 1–2 weeks of initiation, with each dose increase, and at least yearly. 11
• The 2003 AGS diabetes guidelines recommend a target blood pressure <140/80 mm Hg if tolerated, with epidemiologic evidence suggesting <130/80 may provide further benefit. 11

Monitoring Parameters

Renal Function and Electrolytes

• Check serum potassium and creatinine within 1–2 weeks of starting therapy or increasing the dose. 5, 11
• An increase in creatinine up to 50% above baseline, or to 3 mg/dL (266 µmol/L), whichever is greater, is acceptable. 5
• If urea, creatinine, or potassium rise excessively, consider stopping nephrotoxic drugs (e.g., NSAIDs) or non-essential vasodilators. 5
• Potassium levels up to 6.0 mmol/L are acceptable during titration. 5

Blood Pressure

• Asymptomatic low blood pressure does not usually require treatment changes. 5
• If symptomatic hypotension occurs, consider reducing diuretics, nitrates, calcium channel blockers, or other vasodilators. 5
• If no signs of congestion are present, reduce the diuretic dose. 5

Cough

• ACE inhibitor-induced cough is common but rarely requires discontinuation. 5
• When troublesome cough develops (e.g., preventing sleep) and is proven due to ACE inhibition, substitution with an angiotensin receptor blocker can be considered. 5

Important Contraindications and Cautions

• Contraindicated in bilateral renal artery stenosis, history of angioedema with prior ACE inhibitor therapy, and pregnancy. 12
• Avoid initiation when systolic blood pressure is <90 mm Hg or >30 mm Hg below baseline. 13
• Do not combine ACE inhibitors with ARBs and aldosterone antagonists (triple therapy) due to increased harm. 14, 13
• The 2022 Mayo Clinic diabetic kidney disease guidelines state that combination ACE inhibitor plus ARB therapy is not recommended due to lack of additive benefit and increased risks of hyperkalemia and acute kidney injury. 14
• During initiation, avoid concomitant potassium-sparing diuretics, NSAIDs, and COX-2 inhibitors. 13

Common Pitfalls

• Beta-blockers may be used with captopril, but their effects are less than additive. 1
• Angioedema occurs in <1% of patients and is more frequent in Black patients; if it develops, ACE inhibitors should be avoided for life. 13
• Up to 20% of patients may develop ACE inhibitor-induced cough; counsel patients about this possibility. 13
• In severe hypertension requiring rapid control, captopril therapy must be initiated under very close medical supervision. 1